Abbott CEO Robert Ford explains how LAA and diabetes pressures drove Q3 guidance cuts, and what's ahead for 2027 growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results